Patents by Inventor Hubertus Johanus Matheus Klaassen

Hubertus Johanus Matheus Klaassen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
    Patent number: 8673268
    Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: March 18, 2014
    Assignee: Galapagos N.V.
    Inventors: Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen
  • MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20120190570
    Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
    Type: Application
    Filed: January 5, 2012
    Publication date: July 26, 2012
    Applicant: GALAPAGOS NV
    Inventors: Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen
  • Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
    Patent number: 8097408
    Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: January 17, 2012
    Assignee: Galapagos BV
    Inventors: Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen
  • MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20090170720
    Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
    Type: Application
    Filed: January 27, 2009
    Publication date: July 2, 2009
    Applicant: GALAPAGOS NV
    Inventors: Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen
  • Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
    Patent number: 7485468
    Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: February 3, 2009
    Assignee: Galapagos BV
    Inventors: Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen